NASDAQ:PLRZ Polyrizon Q4 2025 Earnings Results & Report $8.99 +0.12 (+1.35%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$9.28 +0.29 (+3.17%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Polyrizon reported Q4 2025 earnings on February 14, 2026. The company reported EPS of -$2.81. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 14, 2026TimeAfter Market Closes Polyrizon EPS ResultsActual EPS-$2.81Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APolyrizon Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Polyrizon Q4 2025 Earnings FAQ Did Polyrizon beat earnings estimates for Q4 2025? Polyrizon (NASDAQ:PLRZ) reported earnings of -$2.81 per share for Q4 2025. The report was announced on Saturday, February 14, 2026. Polyrizon Earnings HeadlinesPolyrizon (NASDAQ:PLRZ) Stock Price Down 3.6% - Here's WhyOctober 6, 2026 | americanbankingnews.comPolyrizon Expands IP Moat With New U.S. Patent Filing for Intranasal Drug-Delivery PlatformOctober 5, 2026 | tipranks.comA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright.October 10 at 1:00 AM | True Market Insiders (Ad)Polyrizon Files New U.S. Patent Application Covering Nasal Drug DeliveryOctober 5, 2026 | rttnews.comPolyrizon Files New U.S. Patent Application for Mucoadhesive Nasal Drug Delivery PlatformOctober 5, 2026 | quiverquant.comQPolyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery PlatformOctober 5, 2026 | globenewswire.comSee More Polyrizon Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Polyrizon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Polyrizon and other key companies, straight to your email. Email Address About PolyrizonPolyrizon (NASDAQ:PLRZ) is a biotechnology company developing nasal and respiratory-care products based on proprietary hydrogel technology. Its platform is designed to create a physical barrier on mucosal surfaces, potentially helping limit exposure to allergens, pollutants, and other airborne particles. The company’s product candidates are focused primarily on intranasal applications, including solutions intended for allergic rhinitis and other upper-respiratory conditions. Polyrizon has described its technology as mucoadhesive, meaning that the hydrogels are designed to remain on nasal surfaces for an extended period while supporting localized protection. Polyrizon is headquartered in Israel and is advancing its platform through product development and clinical or regulatory activities. The company’s programs and commercialization plans remain subject to development, testing, and applicable regulatory approvals.View Polyrizon ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part Begins Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
